Evaluation of antibody targeted controlled release nanoparticle systems

该提案的总体目标是对一种由学术合作伙伴开发的新型抗体药物递送技术进行试点评估(Bioconjug Chem. 2008:19(8):1561-9；Pharm Res. 2008, 25(1):135-46)，使用工业合作伙伴开发的新型治疗性抗体。实现这一目标将提供以下方面：研究员的发展？2.学生的研究专长、管理和领导能力。围绕所产生的数据开发新的专利申请。合作伙伴对一种新的治疗方法进行技术和商业评估。开发数据组合，以促进未来向mrc等机构申请项目拨款。该项目建立在工业和学术合作伙伴之间已建立的联系上。这些团体在过去的合作中取得了成功，产生了共同的知识产权，发表了高质量的期刊（临床癌症研究，生物偶联化学和PlosONE），并最终为当地经济创造了就业机会和财富。先前的合作重点是转移药学院的蛋白质工程技术（通过aKTP计划；在最终报告中获得A奖；2008年地区获奖者），导致该公司开发了新的牛结核病诊断试剂盒，目前正在英国和爱尔兰进行评估。在目前的项目中，学术合作伙伴开发了一种新型纳米颗粒药物输送系统，并且已经提供了商业上不敏感的抗体，作为工业合作伙伴在体外的原理验证。该项目将在此基础上，在相关的体内原发性和转移性肿瘤模型中检测商业上优先考虑的抗体（使用支撑公司的平台技术生产）。我们相信该计划是资助该试点项目的理想机制，因为它不仅提供了承担项目的范围，而且允许研究员学习和支持技术，从而开发自己的CV。并为MRC（如DPFS）提供进一步资助机会提供框架

The overarching objective of this proposal is the pilot evaluation of a novel antibody-drugdelivery technology, developed by the academic partner (Bioconjug Chem. 2008:19(8):1561-9; Pharm Res. 2008:25(1):135-46), using novel therapeutic antibodies that have beendeveloped by the industrial partner. Pursuance of this objective will provide the following:1. Development of the Research Fellow?s research expertise, management and leadership2. Development of new patent applications around the data produced3. Technical and commercial evaluation of a new therapeutic approach by the partners4. Development of a portfolio of data to facilitate future project grant application funding toagencies such as the MRCThis project builds on the established links between the industrial and academic partners.These groups have successfully collaborated in the past, producing joint IP, publications inquality journals (Clinical Cancer Research, Bioconjugate Chemistry and PlosONE), andultimately creating jobs and wealth in the local economy. A previous collaboration, focussedon the transfer of a protein engineering technology from the School of Pharmacy (through aKTP scheme; awarded A in final report; regional winner 2008), led to the development of anew bovine TB diagnostic kit by the company, which is currently undergoing evaluation in theUK and Ireland.In this current project, the academic partner has developed a novel nanoparticulate drugdelivery system and has already been provided with commercially insensitive antibodies totest as a proof of principle in vitro by the industrial partner. This project will build on thisbase, examining commercially prioritised antibodies (produced using the platformtechnologies underpinning the company) in relevant in vivo primary and metastatic tumourmodelsWe believe that this programme is an ideal mechanism to fund this pilot project, as it not onlyprovides the scope to undertake the project, but allows the Fellow to learn and champion thetechnology, thus developing their own CV, and provides a framework for further fundingopportunities from the MRC such as the DPFS